Yesterday I told you about Warren Buffett's Pfizer transaction.
As you may know, Pfizer is a cash cow business with deep liquidity reserves.
Similar to Berkshire Hathaway and another reason Buffett wanted in. Still, while most investors bought the stock at $57 per share, the Oracle got in for roughly $28.
In other words, as an insider, you're not just getting in before most investors…
You're paying — in many cases — at least 50% less than "outsiders."
The less you pay, the more you can buy and the higher your profit margin.
Like the 150 percent yield we saw on a $1 firm revolutionizing the back-pain market.
But it's not just getting a front-row seat to the best the market has to offer.
As an insider, you'll also be one of the first to know when a storm is coming. So you can get out of the way and in some cases, turn a potential loss into a triple-digit winner.
Like how Buffett sold his Pfizer shares in time, before the stock went on a free fall.
Or how we moved cash from a medical startup at the peak of the biotech selloff…
Into Summit Technologies, three weeks before it announced a new licensing deal with a biotech "super major." That move returned 260% in a bad month for many investors.
Most people think these insider wins are reserved for large investors but as I said in my last email, that's no longer true, thanks to an SEC rule that leveled the playing field.
You can learn more about it in this episode of "Insider's exposed."
Talk soon.
Steve Place
|
|
|
|
Post a Comment
Post a Comment